MA49956A - Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak - Google Patents

Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak

Info

Publication number
MA49956A
MA49956A MA049956A MA49956A MA49956A MA 49956 A MA49956 A MA 49956A MA 049956 A MA049956 A MA 049956A MA 49956 A MA49956 A MA 49956A MA 49956 A MA49956 A MA 49956A
Authority
MA
Morocco
Prior art keywords
compounds used
pyrimidine compounds
jak inhibitors
kinase jak
kinase
Prior art date
Application number
MA049956A
Other languages
English (en)
Other versions
MA49956B1 (fr
Inventor
Gary E L Brandt
Marta Dabros
Ryan Hudson
Jennifer Kozak
Robert Murray Mckinnell
Jerry Nzerem
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MA49956A publication Critical patent/MA49956A/fr
Publication of MA49956B1 publication Critical patent/MA49956B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Dental Preparations (AREA)
MA49956A 2017-10-27 2018-10-26 Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak MA49956B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762577852P 2017-10-27 2017-10-27
PCT/US2018/057682 WO2019084383A1 (fr) 2017-10-27 2018-10-26 Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak

Publications (2)

Publication Number Publication Date
MA49956A true MA49956A (fr) 2020-07-01
MA49956B1 MA49956B1 (fr) 2022-11-30

Family

ID=64277858

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49956A MA49956B1 (fr) 2017-10-27 2018-10-26 Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak

Country Status (38)

Country Link
US (7) US10308646B2 (fr)
EP (1) EP3672965B1 (fr)
JP (1) JP7218364B2 (fr)
KR (1) KR102613503B1 (fr)
CN (1) CN111247142B (fr)
AR (1) AR113803A1 (fr)
AU (1) AU2018354370B2 (fr)
BR (1) BR112020008015A2 (fr)
CA (1) CA3074034A1 (fr)
CL (1) CL2020001090A1 (fr)
CR (1) CR20200180A (fr)
CU (1) CU24671B1 (fr)
DK (1) DK3672965T3 (fr)
DO (1) DOP2020000083A (fr)
EA (1) EA202091016A1 (fr)
EC (1) ECSP20023795A (fr)
ES (1) ES2932526T3 (fr)
GE (2) GEP20227344B (fr)
HR (1) HRP20221221T1 (fr)
HU (1) HUE060401T2 (fr)
IL (1) IL274037B2 (fr)
LT (1) LT3672965T (fr)
MA (1) MA49956B1 (fr)
MD (1) MD3672965T2 (fr)
MX (1) MX2020004255A (fr)
NI (1) NI202000032A (fr)
PE (1) PE20201495A1 (fr)
PH (1) PH12020500528A1 (fr)
PL (1) PL3672965T3 (fr)
PT (1) PT3672965T (fr)
RS (1) RS63608B1 (fr)
SG (1) SG11202001706RA (fr)
SI (1) SI3672965T1 (fr)
SM (1) SMT202200409T1 (fr)
TW (1) TWI789446B (fr)
UA (1) UA125130C2 (fr)
WO (1) WO2019084383A1 (fr)
ZA (1) ZA202001641B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3672965T (pt) 2017-10-27 2022-09-29 Theravance Biopharma R&D Ip Llc Composto de pirimidina como inibidor de jak cinase
CN111511738B (zh) * 2018-11-30 2023-01-20 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
ES2974577T3 (es) 2019-04-24 2024-06-27 Theravance Biopharma R&D Ip Llc Compuestos éster y carbonato de pirimidina como inhibidores de JAK quinasa
AR118767A1 (es) * 2019-04-24 2021-10-27 Theravance Biopharma R&D Ip Llc Pirimidinas sustituidas como inhibidores de jak y su uso para el tratamiento de enfermedades inflamatorias o autoinmunes cutáneas
EP4188333A1 (fr) * 2020-07-28 2023-06-07 Arcutis Biotherapeutics, Inc. Formulation topique contenant un inhibiteur de jak et le laureth-4
EP4204411A1 (fr) * 2020-08-26 2023-07-05 Nalo Therapeutics Modulateurs de la protéine proto-oncogène de la famille myc
US20230374124A1 (en) * 2020-10-08 2023-11-23 Icahn School Of Medicine At Mount Sinai Compositions for treatment alopecia areata, biomarkers for treatment success and, methods of use thereof
TW202311256A (zh) * 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
CA3236262A1 (fr) 2021-10-25 2023-05-04 Isaac Marx Agents de degradation de tyk2 et leurs utilisations
EP4447930A1 (fr) 2021-12-15 2024-10-23 Arcutis Biotherapeutics, Inc. Formulations de shr0302 stables
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
CN115487301B (zh) * 2022-11-08 2023-07-07 四川大学华西医院 Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
DK1318997T3 (da) 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
CA2588220A1 (fr) 2004-12-23 2006-06-29 Pfizer Products Inc. Derives heteroaromatiques utiles en tant qu'agents anticancereux
EP1951716B1 (fr) 2005-11-16 2011-05-04 Vertex Pharmaceuticals, Inc. Aminopyrimidines utiles en tant qu inhibiteurs de la kinase
KR20090024270A (ko) 2006-06-30 2009-03-06 아스트라제네카 아베 암 치료에 유용한 피리미딘 유도체
CA2656290A1 (fr) 2006-07-05 2008-01-10 Exelixis, Inc. Procedes d'utilisation de modulateurs de kinase igf1r et abl
KR20140103972A (ko) 2011-12-22 2014-08-27 에프. 호프만-라 로슈 아게 세린/트레오닌 키나아제 억제제로서의 2,4-다이아민-피리미딘 유도체
WO2015094803A1 (fr) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Composés hétéroaryles substitués et méthodes d'utilisation
NO2721710T3 (fr) * 2014-08-21 2018-03-31
WO2016052930A1 (fr) * 2014-09-30 2016-04-07 한미정밀화학주식회사 Procédé de préparation de (r)-9-[2-(phosphonométhoxy)propyl]adénine de grande pureté
JP6692836B2 (ja) * 2015-05-28 2020-05-13 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
WO2017189822A1 (fr) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Composés de pyridine à titre d'inhibiteurs de kinases jak
PT3672965T (pt) * 2017-10-27 2022-09-29 Theravance Biopharma R&D Ip Llc Composto de pirimidina como inibidor de jak cinase
AR118767A1 (es) 2019-04-24 2021-10-27 Theravance Biopharma R&D Ip Llc Pirimidinas sustituidas como inhibidores de jak y su uso para el tratamiento de enfermedades inflamatorias o autoinmunes cutáneas
ES2974577T3 (es) 2019-04-24 2024-06-27 Theravance Biopharma R&D Ip Llc Compuestos éster y carbonato de pirimidina como inhibidores de JAK quinasa

Also Published As

Publication number Publication date
JP2021501151A (ja) 2021-01-14
DK3672965T3 (da) 2022-10-03
LT3672965T (lt) 2022-10-10
CA3074034A1 (fr) 2019-05-02
ES2932526T3 (es) 2023-01-20
PL3672965T3 (pl) 2023-01-16
HRP20221221T1 (hr) 2022-12-09
CN111247142A (zh) 2020-06-05
TWI789446B (zh) 2023-01-11
CU24671B1 (es) 2023-07-12
US20220396573A1 (en) 2022-12-15
US11420965B2 (en) 2022-08-23
CL2020001090A1 (es) 2020-08-21
US11814377B2 (en) 2023-11-14
US20200369660A1 (en) 2020-11-26
US20210214349A1 (en) 2021-07-15
US20200140430A1 (en) 2020-05-07
KR102613503B1 (ko) 2023-12-13
US12172994B2 (en) 2024-12-24
JP7218364B2 (ja) 2023-02-06
EA202091016A1 (ru) 2020-07-17
AR113803A1 (es) 2020-06-10
TW201930304A (zh) 2019-08-01
US10988470B2 (en) 2021-04-27
NI202000032A (es) 2020-10-09
US10774080B2 (en) 2020-09-15
IL274037A (en) 2020-06-30
CN111247142B (zh) 2022-12-02
US20190127364A1 (en) 2019-05-02
SMT202200409T1 (it) 2022-11-18
US10308646B2 (en) 2019-06-04
BR112020008015A2 (pt) 2020-10-27
AU2018354370B2 (en) 2023-04-27
GEP20227344B (en) 2022-01-25
SI3672965T1 (sl) 2022-11-30
HUE060401T2 (hu) 2023-02-28
US20240158389A1 (en) 2024-05-16
SG11202001706RA (en) 2020-03-30
DOP2020000083A (es) 2020-08-15
EP3672965A1 (fr) 2020-07-01
US10562894B2 (en) 2020-02-18
WO2019084383A1 (fr) 2019-05-02
PT3672965T (pt) 2022-09-29
ZA202001641B (en) 2021-04-28
RS63608B1 (sr) 2022-10-31
CR20200180A (es) 2020-08-12
US20190241555A1 (en) 2019-08-08
CU20200053A7 (es) 2021-03-11
PH12020500528A1 (en) 2021-06-07
AU2018354370A1 (en) 2020-04-09
MD3672965T2 (ro) 2022-12-31
ECSP20023795A (es) 2020-06-30
EP3672965B1 (fr) 2022-09-07
UA125130C2 (uk) 2022-01-12
IL274037B1 (en) 2023-07-01
IL274037B2 (en) 2023-11-01
KR20200078517A (ko) 2020-07-01
PE20201495A1 (es) 2020-12-29
GEAP202115340A (en) 2021-08-10
MX2020004255A (es) 2020-07-29
MA49956B1 (fr) 2022-11-30

Similar Documents

Publication Publication Date Title
MA49956A (fr) Composés de pyrimidine utilisés en tant qu&#39;inhibiteurs de kinase jak
FR24C1009I2 (fr) Composés utilisés comme inhibiteurs de kinase
MA51846A (fr) Composés hétérocycliques utilisés en tant qu&#39;inhibiteurs de kinases
MA49888A (fr) Composés macrocycliques utilisés en tant qu&#39;inhibiteurs de kinase ros1
MA47013A (fr) Composés benzolactames utilisés en tant qu&#39;inhibiteurs de protéine kinase
MA52486A (fr) Pyridazinones utilisés en tant qu&#39;inhibiteurs de parp7
MA47099A (fr) Composés hétéroaromatiques bicycliques utilisés en tant qu&#39;immunomodulateurs
MA43169A (fr) Composés hétérocycliques utilisés en tant qu&#39;inhibiteurs de pi3k-gamma
MA51438A (fr) Composés hétérocycliques utilisés en tant qu&#39;inhibiteurs de lsd1
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu&#39;inhibiteurs de vanine
MA46045A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA42919A (fr) Composés bicycliques utilisés en tant qu&#39;inhibiteurs d&#39;atx
MA45669A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA44860A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA45375A (fr) Composés hétérocycliques utilisés en tant qu&#39;agents antibacteriens
MA55194A (fr) Composés hétérocycliques en tant qu&#39;immunomodulateurs
MA40587A (fr) Composés d&#39;aminopyrimidinyle en tant qu&#39;inhibiteurs de jak
MA42918A (fr) Composés bicycliques utilisés en tant qu&#39;inhibiteurs d&#39;atx
MA42990A (fr) Composés utiles en tant qu&#39;immunomodulateurs
MA45377A (fr) Composés hétérocycliques en tant qu&#39;agents antibacteriens
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu&#39;inhibiteurs de fgfr4
MA42592A (fr) Utilisation de dérivés de 2-(pyrazolopyridin-3-yl) pyrimidine en tant qu&#39;inhibiteurs de jak
MA49570A (fr) Composés bicycliques pyrazolo et triazolo utilisés en tant qu&#39;inhibiteurs de kinase jak
EP3733671A4 (fr) Dérivés amino-fluoropipéridines utilisés en tant qu&#39;inhibiteur de kinase
EP3733673A4 (fr) Dérivés d&#39;oxy-fluoropipéridine utilisés en tant qu&#39;inhibiteur de kinase